

Supplemental tables

Table S1: Murine gene specific primers used in quantitative real-time PCR.

| Primer name | Sequences (3' - 5') |
|--------------------|--|
| <i>NRF2</i> | GAG TCG CTT GCC CTG GAT ATC TCA TGG CTG CCT CCA GAG AA |
| <i>HMOX1</i> | TGA AGC AGG CAT CTG AGG G CGA AGG TGG AAG AGT GGG AG |
| <i>NQO1</i> | GGC ATC CAG TCC TCC ATC AA GTT AGT CCC TCG GCC ATT GTT |
| <i>CAT</i> | CAG AGA GCG GAT TCC TGA GAG A CTT TGC CTT GGA GTA TCT GGT GAT |
| <i>SOD1</i> | GAA ACA AGA TGA CTT GGG CAA AG TTA CTG CGC AAT CCC AAT CA |
| <i>GPX2</i> | GTG GCG TCA CTC TGA GGA ACA CAG TTC TCC TGA TGT CCG AAC TG |
| <i>TRX</i> | GCT AGA GAA GAT GGT CGC CAA GCA GCA TCC TCG TCC TTG ATC CCC ACA AAC TTG |
| <i>GSR</i> | TCG GAA TTC ATG CAC GAT CA GGC TCA CAT AGG CAT CCC TTT |
| <i>iNOS</i> | CCT GGT ACG GGC ATT GCT GCT CAT GCG GCC TCC TTT |
| <i>eNOS</i> | TCA GCC ATC ACA GTG TTC CC ATA GCC CGC ATA GCG TATC AG |
| <i>CD31</i> | CTG CCA GTC CGA AAA TGG AAC CTT CAT CCA CCG GGG CTA TC |
| <i>KGF (FGF7)</i> | ACC TGA GGA TTG ACA AAC GAG G CCA CGG TCC TGA TTT CCA TGA |
| <i>bFGF (FGF2)</i> | TCC AGT TGG TAT GTG GCA CTG A CAG TAT GGC CTT CTG TCC AGG TC |
| <i>COX2</i> | TGC CTG GTC TGA TGA TGT ATG CCA AGT AGT CGC ACA CTC TGT TGT GCT |
| <i>Artn1</i> | CCC TAG CTG TTC TAG CCC TG AGG GTT CTT TCG CTG CAC AA |
| <i>Edn1</i> | TTT CCC GTG ATC TTC TCT CTG C CTG AGT TCG GCT CCC AAG AC |
| <i>CTNNB1</i> | CCC AGT CCT TCA CGC AAG AG CAT CTA GCG TCT CAG GGA ACA |
| <i>CDH5</i> | CCA CTG CTT TGG GAG CCT T GGC AGG TAG CAT GTT GGG G |
| <i>IL-1b</i> | GCA ACT GTT CCT GAA CTC AAC T ATC TTT TGG GGT CCG TCA ACT |
| <i>IL-4</i> | GGT CTC AAC CCC CAG CTA GT GCC GAT GAT CTC TCT CAA GTG AT |
| <i>IL-6</i> | ATC CAG TTG CCT TCT TGG GAC TGA TAA GCC TCC GAC TTG TGA AGT GGT |

| | |
|----------------------------------|--|
| <i>MCP-1</i> | TGA TCC CAA TGA GTA GGC TGG AG ATG TCT GGA CCC ATT CCT TCT TG |
| <i>TNFα</i> | TCT CAT GCA CCA CCA TCA AGG ACT ACC ACT CTC CCT TTG CAG AAC TCA |
| <i>TGFβ</i> | TTT GGA GCC TGG ACA CAC AGT ACA TGT GTT GGT TGT AGA GGG CAA GGA |
| <i>p53</i> | AAA GGA TGC CCA TGC TAC AGA GGA AGG ATT GTG TCT CAG CCC TGA AGT |
| <i>BAX</i> | ACA GCA ATA TGGA GCT GCA GAG GA TGT CCA GCC CAT GAT GGT TCT GAT |
| <i>CDKN1A</i> | GGA ATT GGA GTC AGG CGC AGA T GAA GAG ACA ACG GCA CAC TTT GCT |
| <i>GADD45α</i> | TCA GCG CAC GAT CAC TGT C CCA GCA GGC ACA ACA CCA C |
| <i>GAPDH</i> | CAT GGC CTC CAA GGA GTA AG TGT GAG GGA GAT GCT CAG TG |

Table S2: Cold plasma promoted wound closure of dermal full-thickness wounds (* $p < 0.05$; ** $p < 0.01$).

| Groups/days | | d3 | d6 | d9 | d12 |
|-------------|-------------------------------|----------|----------|---------|--------|
| ♂ | ctrl | 19+2.1 | 47+3.0 | 70+2.7 | 88+1.8 |
| | 3 s | 22+4.0 | 61+3.7** | 81+2.7* | 92+2.4 |
| | 20 s | 20+2.9 | 49+5.1 | 80+2.9* | 90+3.9 |
| | H ₂ O ₂ | 17+3.8 | 45+3.2 | 78+2.5 | 85+1.6 |
| ♀ | ctrl | 28+3.8 | 48+3.5 | 75+3.5 | 94+1.3 |
| | 3 s | 48+4.6** | 67+4.9** | 92+2.2* | 97+1.2 |
| | 20 s | 38+6 | 61+5.4 | 86+3.2* | 95+2.5 |
| | H ₂ O ₂ | 33+5.2 | 57+3.7 | 87+3.1 | 97+1.9 |

Supplemental figures and figure legends




Figure S1. Schematic visualization of skin wound and study design for plasma treatment. (A) To analyze the molecular and cellular mechanisms of wound healing, we used an immunocompetent SKH1 mouse model. On both ears, full-thickness circular wounds were created using a microscissor Hematoxylin and eosin (H&E) staining of ear wounds on day 0. Schema of wounds on day 0 (lower figure). (B) After wounding, wounds were plasma-treated every third day with a kINPen jet generating

a plethora of reactive species (specified in the star) depending on the treatment time (3 s or 20 s) and compared to placebo (argon gas), H₂O₂ (1 mM), or untreated controls. At days 6 or 15, tissue was removed (dashed line region) for further cellular and molecular biological analyses. (C) No scarring was obtained in plasma-treated animals. (D) Visualization of sunburn cells (arrow heads) in H&E staining, collagen fibers in picrosirius red and collagen staining, and γ H2AX immune fluorescence. Scale bars 1 cm (C), 100 μ m (D); n_≥8.




Figure S2. Changes in mRNA expression following siRNA knockdown targeting NRF2 in keratinocytes. (A) One representative picture of primary keratinocytes two, eight, or 14 days after isolation from SKH1 mouse skin (n=6). (B) Transfection of GFP plasmid into keratinocytes after 72 h. (C) NRF2 and KEAP1 expression after siRNA knockdown targeting Nrf2 and Keap1, respectively. (D) Cells were transfected with siNRF2 and evaluated for *VEGFA*, *HBEGF*, *KGF*, *CSF2*, and *IL-6/8* mRNA expression by qPCR without (-) and with (+) plasma treatment. The mRNA level of scrambled siRNA (black line) were set to 1.14 and the mock control without siRNA was 1 (dashed line). At least three independent experiments were performed and statistically compared to the scrambled siRNA (**p* < 0.05). Scale bar 100 μ m (A), 50 μ m (B).




Figure S3. Nrf2 protein expression analysis using Western blot. One representative Western blot is shown for Nrf2 (**A**) and GAPDH/vinculin (**B**) expression ($n \geq 3$).